Clinical trials: Chemotherapy-Related Nausea and/or Vomiting
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Child
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
Chemotherapy-induced nausea and vomiting, sleep quality and pain are the common symptoms experienced by children with cancer. These symptoms significantly devastate the children's quality of life.
- Conditions
- Neoplasms, Child, Nausea, Vomiting
- Trial name
- NCT04853303
- Testing
- Hypnosis VR
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
RATIONALE: Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Trial name
- NCT01031953
- Testing
- fosaprepitant dimeglumine, systemic chemotherapy, survey administration
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- OHSU Knight Cancer Institute
Pain, Nausea With Vomiting Chemotherapy-Induced
The Effect of Acupressure on Pain, Nausea-Vomiting, and Mental Well-Being in Oncology Patients
The goal of this clinical trial is to compare the effect of self acupressure and acupressure applied by therapists on pain, nausea-vomiting, and mental well-being in oncology patients.
- Conditions
- Pain, Nausea With Vomiting Chemotherapy-Induced, Mental Health Wellness 1
- Trial name
- NCT05898880
- Testing
- Self-acupressure, Acupressure by therapists, Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 96 people
- Sponsor
- Mersin University
Chemotherapy-induced Nausea and Vomiting
Phase II Proof-of-concept Study of APD421
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
- Trial name
- NCT01303978
- Testing
- APD421
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Acacia Pharma Ltd
Chemotherapy-induced Nausea and Vomiting
Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life and may affect patients' treatment decisions.
- Trial name
- NCT04085393
- Testing
- GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Chemotherapy-induced Nausea and Vomiting
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
The purpose of this study is to investigate the effectiveness of intravenous fosaprepitant therapy to reduce nausea and vomiting during the treatment of high dose interleukin-2 (HD IL-2) therapy for metastatic melanoma or…
- Trial name
- HDIL2/Emend (NCT01874119)
- Testing
- Fosaprepitant
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- St. Louis University
Chemotherapy-induced Nausea and Vomiting
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting.
- Trial name
- NCT05199818
- Testing
- Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg
- Where
- 13 sites in United States
- Volunteers
- 328 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Nausea
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting
phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin can improve the complete control of nausea and vomiting (primary end point)
- Trial name
- NCT04181346
- Testing
- Pregabalin
- Where
- Brazil
- Volunteers
- 82 people
- Sponsor
- Faculdade de Medicina do ABC
Chemotherapy-induced Nausea and Vomiting
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
To compare the antiemetic combination of palonosetron, dexamethasone, and aprepitant (PDA) with antiemetic combination of palonosetron and dexamethasone (PD) in nasopharyngeal carcinoma patients receiving docetaxel, cisplatin…
- Trial name
- CINV (NCT02933099)
- Testing
- Aprepitant+palonosetron+dexamethasone, palonosetron+dexamethasone
- Volunteers
- 300 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic…
- Trial name
- NCT01031498
- Testing
- Ondansetron, Palonosetron
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
- Trial name
- PTCA199-5 (NCT06017284)
- Testing
- Thalidomide, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Sarcoma, Chemotherapy-induced Nausea and Vomiting
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
The goal of this clinical research study is to learn how different doses of fosaprepitant may effect how ifosfamide-based chemotherapy is absorbed by the body.
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Trial name
- NCT01490060
- Testing
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Nausea, Vomiting
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
This is an efficacy and safety study to compare aprepitant with ondansetron for the prevention of nausea and vomiting in the first cycle of moderately emetogenic chemotherapy (MEC) in participants with solid tumors.
- Trial name
- KMEC (NCT01636947)
- Testing
- Aprepitant, Ondansetron, Dexamethasone
- Volunteers
- 494 people
- Sponsor
- Merck Sharp & Dohme LLC
Nausea and Vomiting Chemotherapy-Induced
Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy
The goal of this observational study is to evaluate the associations between patient-directed medical cannabis use and chemotherapy-induced nausea and vomiting (CINV), as well as other treatment-related symptoms, among patients…
- Trial name
- MOSAIC (NCT07374939)
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Rochester
Nausea, Vomiting
Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
- Conditions
- Nausea, Vomiting, Breast Neoplasms
- Trial name
- NCT00092196
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days
- Volunteers
- 820 people
- Sponsor
- Merck Sharp & Dohme LLC
Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis
To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo
- Trial name
- OLN-EME (NCT04232423)
- Testing
- Olanzapine 10 Mg ORAL TABLET, Olanzapine 5 Mg ORAL TABLET
- Where
- Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Chemotherapy-induced Nausea and Vomiting
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion…
- Trial name
- NCT03403712
- Testing
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Where
- 40 sites in United States, Georgia
- Volunteers
- 404 people
- Sponsor
- Helsinn Healthcare SA
Cervical Cancer, Nasopharyngeal Cancer
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly…
- Conditions
- Cervical Cancer, Nasopharyngeal Cancer, Chemotherapy-induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiting
- Trial name
- NCT05564286
- Testing
- Fosaprepitant, tropisetron, Dexamethasone
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shantou University Medical College
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC